A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7252 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2019
At a glance
- Drugs MK-7252 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 24 Dec 2018 Status changed from active, no longer recruiting to completed.
- 13 Dec 2018 Planned End Date changed from 13 Dec 2018 to 20 Dec 2018.
- 13 Dec 2018 Planned primary completion date changed from 13 Dec 2018 to 20 Dec 2018.